News
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...
For many rare disease patients and their families, this often results in years of uncertainty, misdiagnosis, and limited or ...
The study’s findings could significantly impact AstraZeneca’s market position by potentially enhancing its reputation in heart failure treatment, influencing stock performance positively. As the ...
The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...
Seasoned communications leader Rikki Jones joins biopharmaceutical giant AstraZeneca as Head of Communications, International ...
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.
Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...
InsideNoVa on MSN9d
AstraZeneca to build its largest-ever manufacturing facility in Virginia, creating hundreds of jobsIn a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...
AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...
TipRanks on MSN19h
AstraZeneca’s Innovative Propellant Study: Market Implications and Future ProspectsFrom a market perspective, the successful completion of this study could positively influence AstraZeneca’s stock performance by showcasing its commitment to advancing respiratory therapies. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback